Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebralcare pills placebo is an inactive control substance used in clinical research, specifically within the CABLE trial (CerebrAlcare Pills on CereBral Small VesseL DiseasE) led by Beijing Tiantan Hospital. It is formulated to be indistinguishable in appearance, odor, and taste from the active Cerebralcare pills (also known as Yangxue Qingnao), which is a traditional Chinese medicine (TCM) product developed by Tasly Pharmaceutical Group. In the context of cerebral small vessel disease (CSVD), this placebo serves as a negative control to evaluate the therapeutic efficacy of the active medication on cognitive function and structural MRI markers, ensuring that observed effects are not due to the placebo effect or investigator bias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cerebralcare pills placebo.